Anderson Kenneth Carl 4

What Happened
Kenneth C. Anderson, a director of C4 Therapeutics (CCCC), exercised stock options on June 1, 2026. He exercised options to acquire 1,070 shares at an exercise price of $2.11 per share, for a total cash outlay of $2,258. The filing indicates no shares were sold in connection with the exercise.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-04. (Filed within the normal reporting window.)
• Action: Option exercise (transaction code M). 1,070 shares acquired at $2.11 each; total cost $2,258.
• A derivative entry at $0 reflects the option converting into stock (no cash sale of shares).
• Footnotes: F1 confirms exercise for cash and no shares sold; F7 notes the underlying options were fully vested and exercisable. F2–F6 note certain shares are held in revocable/irrevocable trusts in which the reporting person disclaims beneficial ownership except for pecuniary interest.
• Shares owned after the transaction: not specified in this filing.

Context
This was a straightforward option exercise (paying cash to convert options into shares), not a cashless or immediate sale. Such exercises are common for insiders realizing vested equity and do not by themselves indicate a buy or sell signal about the company's prospects.